Nurix Therapeutics, Inc. Income Statement

Income Statement Nov2019 Nov2020 Nov2021 Nov2022 Nov2023 Nov2024
Revenue & cost
Revenue 31.11M17.82M29.75M38.63M76.99M54.55M
Gross Profit 31.11M17.82M29.75M38.63M76.99M54.55M
Operating items
Research & Development 45.02M66.49M116.43M184.50M189.15M221.63M
Selling, General & Administrative 8.33M16.31M31.20M38.00M42.90M45.94M
Operating Expenses 53.35M82.80M147.64M222.49M232.05M267.58M
Operating Income -22.24M-64.98M-117.89M-183.87M-155.06M-213.03M
EBIT -22.24M-64.98M-117.89M-183.87M-155.06M-213.03M
Non-operating items
Interest & Investment Income 0.78M1.21M0.82M3.51M11.12M19.73M
Net income details
EBT -21.46M-63.78M-117.06M-180.36M-143.95M-193.30M
Tax Provisions 0.24M-20.58M0.13M0.27M
Profit After Tax -21.70M-43.24M-117.19M-180.36M-143.95M-193.57M
Income from Continuing Operations -21.70M-43.20M-117.19M-180.36M-143.95M-193.57M
Consolidated Net Income -21.70M-43.20M-117.19M-180.36M-143.95M-193.57M
Income towards Parent Company -21.70M-43.20M-117.19M-180.36M-143.95M-193.57M
Net Income towards Common Stockholders -21.70M-43.20M-117.19M-180.36M-143.95M-193.57M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 37.04M38.86M44.61M47.27M48.50M70.84M
Shares Outstanding (Diluted Average) 42.90M48.61M54.34M67.12M
EBITDA -22.24M-64.98M-117.89M-183.87M-155.06M-213.03M
Shares Outstanding 3.60M38.86M44.66M47.17M48.72M75.87M
Tax Rate 0.00M